Skip to main
IMAB
IMAB logo

I-Mab (IMAB) Stock Forecast & Price Target

I-Mab (IMAB) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

I-MAB's stock outlook is bolstered by the promising Phase 2 study results of uliledlimab, which demonstrated a favorable safety profile and an objective response rate (ORR) of 31% across all patients, indicating strong potential for success in treating solid tumors. Additionally, the encouraging Phase 1 pharmacokinetic/pharmacodynamic data reveal full target engagement for uliledlimab, showing a positive correlation between drug exposure and ORR in metastatic non-small cell lung cancer patients, adding to the bullish sentiment surrounding this program. Furthermore, Givastomig continues to demonstrate a favorable safety profile and favorable pharmacokinetics, suggesting that its ongoing development could significantly enhance I-MAB's valuation and present additional upside potential.

Bears say

I-Mab experienced a significant decrease in revenue, reporting no revenues in the third quarter of 2024, down from $0.31 million in the same period the previous year. The company's net losses have widened, showing a loss of $(20.5) million for the third quarter and $(38.9) million for the nine-month period ended September 30, 2024, compared to $(8.2) million and $(45.3) million respectively for the prior year. Additionally, the presence of serious treatment-related adverse events, along with the limited clinical utility of certain candidates due to toxicity issues, raises concerns about the viability and future success of its drug pipeline.

I-Mab (IMAB) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of I-Mab and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About I-Mab (IMAB) Forecast

Analysts have given I-Mab (IMAB) a Strong Buy based on their latest research and market trends.

According to 8 analysts, I-Mab (IMAB) has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

I-Mab (IMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.